Date published: 2025-9-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

NFXL1 Inhibitors

Nuclear transcription factor X-box binding-like 1 (NFXL1) is a protein that plays a crucial role in the regulation of gene expression within the nucleus of cells. As part of the NFX family of transcription factors, NFXL1 is involved in diverse cellular processes, including the maintenance of genomic stability, cell cycle regulation, and the stress response. Its ability to bind specific DNA sequences allows it to control the transcription of genes that are critical for these cellular functions. The activity and function of NFXL1 are modulated through its interaction with various cofactors and its post-translational modifications, which collectively determine its ability to influence gene expression patterns and cellular outcomes.

The inhibition of NFXL1 involves mechanisms that disrupt its role in gene transcription regulation, either by directly interfering with its DNA-binding capacity or by affecting its interaction with cofactors necessary for its transcriptional activity. Inhibition can occur through the alteration of its protein structure or post-translational modifications, which can affect its localization, stability, or ability to form complexes with other proteins. Additionally, the regulation of NFXL1 can be indirectly influenced by signaling pathways that modulate its expression levels or the availability of its cofactors. Such inhibitory mechanisms are essential for understanding how the regulation of NFXL1 can influence cellular processes and the maintenance of cellular homeostasis. Through these complex regulatory networks, cells can finely tune the activity of NFXL1, ensuring precise control over gene expression patterns that are vital for cellular function and response to environmental cues.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Triptolide

38748-32-2sc-200122
sc-200122A
1 mg
5 mg
$88.00
$200.00
13
(1)

Triptolide is a diterpene triepoxide that inhibits transcription factors by preventing RNA polymerase II activation and may affect NFXL1 by altering its transcriptional activity.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Sirolimus is an mTOR inhibitor that affects protein synthesis and could indirectly influence NFXL1 expression by modulating upstream signaling pathways.

MG-132 [Z-Leu- Leu-Leu-CHO]

133407-82-6sc-201270
sc-201270A
sc-201270B
5 mg
25 mg
100 mg
$56.00
$260.00
$980.00
163
(3)

MG132 is a proteasome inhibitor that can stabilize proteins including transcription factors, potentially affecting NFXL1 levels and activity.

(±)-JQ1

1268524-69-1sc-472932
sc-472932A
5 mg
25 mg
$226.00
$846.00
1
(0)

JQ1 is a BET bromodomain inhibitor that impacts transcription regulation and might indirectly influence NFXL1's role in gene expression.

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

5-Azacytidine is a DNA methyltransferase inhibitor which can alter gene expression patterns and possibly NFXL1's function as well.

Cycloheximide

66-81-9sc-3508B
sc-3508
sc-3508A
100 mg
1 g
5 g
$40.00
$82.00
$256.00
127
(5)

Cycloheximide is a protein synthesis inhibitor that could decrease the overall levels of proteins, including NFXL1.

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$73.00
$238.00
$717.00
$2522.00
$21420.00
53
(3)

Actinomycin D binds to DNA and inhibits RNA polymerase, which could reduce NFXL1's ability to regulate gene transcription.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

PD98059 is an MEK inhibitor that can modulate the MAPK/ERK pathway, potentially affecting NFXL1's transcriptional activity.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY294002 is a PI3K inhibitor that may alter the AKT pathway, which can influence transcription factors including NFXL1.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

U0126 is another MEK inhibitor that could affect NFXL1 activity by altering MAPK/ERK pathway signaling.